Lawsuit Claims Abbott Sales Reps Practiced Medicine Without a License While Adjusting Spinal Cord Stimulator
A South Carolina woman has filed a product liability lawsuit against Abbott Laboratories, alleging that unlicensed sales representatives practiced medicine without a license by repeatedly reprogramming her failed Proclaim spinal cord stimulator (SCS) rather than recommending its removal. The plaintiff, Tonia Holley, endured years of pain and electric shocks, only to discover later that the device's leads had migrated, making reprogramming futile. This lawsuit will join other similar Abbott SCS implant lawsuits in a multidistrict litigation (MDL).
Abbott starts trial of Encantor transcatheter aortic valve
Abbott has initiated the VOYAGER CE clinical trial for its investigational Encantor transcatheter aortic valve implantation system in Europe and Australia, targeting up to 300 severe aortic stenosis patients. This balloon-expandable system differentiates from Abbott's existing self-expanding Navitor TAVI system and aims to provide physicians with greater control and procedural confidence. The company plans a pivotal U.S. trial soon and will share early feasibility study data at PCR London Valves 2026.
Science Corporation garners $400M and more funding news
Neural engineering company Science Corporation has secured $400 million in Series D funding, bringing its total to over $900 million. Additionally, Hone Health raised $228 million in equity and growth financing to expand its health and longevity platform, and Remedy Robotics secured $62 million in Series B funding to advance its AI robotic systems for cardiovascular care. These funds will support product development, market expansion, and clinical trials for all three companies.
Global Point-of-Care Connectivity Solutions Market to Reach $1.7 Billion by 2032 | Abbott, Roche, Siemens Healthineers and GE HealthCare Accelerate AI-Driven Care
The global point-of-care connectivity solutions market is projected to grow from $1.1 billion in 2025 to $1.7 billion by 2032, driven by healthcare digitization and demand for real-time patient data. Key players like Abbott, Roche, Siemens Healthineers, and GE HealthCare are leveraging AI and other advanced technologies to enhance these solutions. The market is segmented by offering, application, end-use, and geography, with significant growth expected in the software segment and the China market.
MedTech poised to outperform in 2027, Leerink says as Abbott upgraded
Leerink Partners upgraded Abbott Laboratories (ABT) to Outperform, anticipating significant gains for the MedTech sector over the next 12–24 months. The firm expresses growing conviction that MedTech will deliver outsized returns, driven by multiple favorable factors. This upgrade suggests a positive outlook for Abbott and the broader medical technology industry.
Earnings Beat Might Change The Case For Investing In Stryker (SYK)
Stryker (SYK) reported strong third-quarter results with 10.3% adjusted EPS growth driven by margin gains and cost control, particularly from Endoscopy, Medical, and Mako orthopaedics. The company is focusing on robotics and strategic board appointments to support its defensive growth narrative. Despite ongoing operational and sentiment risks like debt and insider selling, the latest performance indicates that Stryker's strategy remains effective.
Gix Internet Launches Carelee, a Physical AI Platform for
Gix Internet Ltd., through its subsidiary deliverz.ai, has launched Carelee, an AI-assisted workforce orchestration platform for hospital-at-home programs. This platform aims to streamline caregiver dispatch, visit assignment, and route optimization in the growing $169 billion U.S. home health care sector. Carelee offers both marketplace and automatic assignment modes, providing real-time visibility and leveraging Gix's Physical AI strategy to extend intelligent orchestration beyond hospital logistics to in-home care.
SINTX advances additive manufacturing platform for patient-specific implants
SINTX Technologies Inc. is progressing with its SiNERGY additive manufacturing platform, combining silicon nitride-based biomaterials with medical-grade PEEK for patient-specific implants. The company has built out its 3D printing facility, received new AM systems, and anticipates receiving proprietary SiN/PEEK filament by year-end 2026, with plans for FDA clearance and commercialization in early 2027. This initiative aims to deliver personalized orthopedic solutions leveraging the unique biological and mechanical properties of silicon nitride.
Medtronic (MDT) Declines More Than Market: Some Information for Investors
Medtronic (MDT) closed down 1.56% at $100.72, underperforming the S&P 500, which lost 0.23%. Despite the daily decline, MDT has risen 8.13% over the past month, surpassing the Medical sector's gain and the S&P 500's loss. Investors are anticipating Medtronic's earnings announcement on November 24, 2026, with projected EPS of $1.34 and revenue of $9.46 billion.
Selling stockholders may offer up to 9.10M Anteris (AVR) shares; Q3 net loss reached $26.8M.
Anteris Technologies Global Corp. (AVR) has updated its resale prospectus to include up to 9.10 million common shares offered by selling stockholders, following the filing of its quarterly report for Q3 2026. The company reported increased net sales to $519,000 but also a wider net loss of $26.8 million for the quarter, an increase from $22.2 million a year prior. Anteris is continuing its PARADIGM heart-valve trial and has secured additional manufacturing capacity, but material weaknesses in internal controls remain unremediated.
Medtronic PLC stock outperforms competitors despite losses on the day
Medtronic PLC (MDT) shares dropped 1.56% to $100.72 on Wednesday, marking its second consecutive day of losses. Despite this decline, the stock outperformed the broader market, as the S&P 500 Index fell 0.23% and the Dow Jones Industrial Average dropped 1.11% on the same day.
Should You Continue to Hold Medtronic Stock in Your Portfolio?
Medtronic (MDT) is positioned for growth in its MedSurg and Neuroscience segments, driven by advancements like Hugo adoption, digital surgery, and new product launches, particularly in international markets. However, the company faces headwinds from macroeconomic pressures, product mix shifts, and foreign exchange fluctuations. Despite these challenges, Medtronic has consistently surpassed earnings estimates and maintains a positive outlook for fiscal 2027.
Douglas Roeder Bought 10% More Shares In Senseonics Holdings
Independent Non-Management Director Douglas Roeder recently purchased US$176k worth of Senseonics Holdings (NASDAQ:SENS) stock at US$10.32 per share, increasing his holding by 10%. This was the largest insider purchase in the last year, indicating optimism even at a higher price than the current US$10.16. Insiders collectively own about 8.4% of the company, suggesting alignment with shareholders, despite the company reporting a loss last year.
FDA clears Medtronic’s Hugo robotic system for general surgery
The US Food and Drug Administration (FDA) has granted clearance to Medtronic's Hugo robotic-assisted surgery (RAS) system for use in all upper abdominal general surgical procedures. This expands the system's application beyond its previous urological indications, now including operations like small bowel resection, cholecystectomy, Roux-en-Y gastric bypass, ventral hernia repairs, appendectomy, and inguinal hernia procedures. The Hugo system, which is already experiencing rapid growth outside the US, features modular robotic arms and an open console design, and can be used with Medtronic tools such as the LigaSure RAS Maryland instrument.
Former Medtronic Executive Joins Teleflex’s Board of Directors
Teleflex Incorporated has appointed Sean M. Salmon, a former Medtronic executive with over 30 years of experience in the medical device and pharmaceutical industries, to its Board of Directors. Salmon will serve on the newly established Growth and Operating Committee, aiming to support Teleflex's strategic transformation, operational execution, and growth initiatives. His extensive background in various aspects of the medtech industry, including commercial operations, R&D, and financial strategy, is expected to provide valuable insights to the board.
Sintx Technologies, Inc. (SINT) stock price, news, quote and history
Sintx Technologies, Inc. (SINT) stock closed at $1.2050, down 2.82%, with a market cap of $9.108 million. The company, which specializes in silicon nitride biomaterials for medical and other applications, has seen significant negative returns over the past year, with a 1-year return of -63.48% and a 5-year return of -99.99%. Analysts maintain a "Buy" rating with a target price of $12.50.
Insulin Delivery Devices Market to Reach US$ 43.11 Billion
The global insulin delivery devices market is projected to grow from US$ 22.04 billion in 2025 to US$ 43.11 billion by 2033, exhibiting an 8.8% CAGR, driven by the increasing prevalence of diabetes and technological advancements. North America leads the market with a 43.50% share, while Asia-Pacific is expected to experience the fastest growth. Key players like Medtronic, Insulet Corporation, and Tandem Diabetes Care are innovating with smart pens, automated insulin delivery systems, and wearable devices to improve diabetes management.
Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
Orchestra BioMed Holdings, Inc. announced its participation in the Piper Sandler 38th Annual Healthcare Conference. David Hochman, Chairman and CEO, will host a fireside chat on December 2, 2026, and management will also conduct one-on-one meetings with investors. The company will provide a live webcast of the fireside chat on its Investor Relations website.
Is NPCE Worth Buying Now as Growth Potential Meets Execution Risk?
NeuroPace, Inc. (NPCE) presents a mixed investment opportunity, with a valuation discount attracting investors but ongoing losses and uneven revenue growth raising concerns. While the company expands its prescriber base and has a promising pipeline, recent third-quarter results showed weaker implant activity and commercial disruptions. The investment case hinges on NeuroPace's ability to improve commercial execution and translate physician interest and pipeline developments into consistent procedure growth.
Electroceutical Devices Market Size, Share & Forecast 2036
The electroceutical devices market is projected to grow from USD 25.1 billion in 2026 to USD 49.2 billion by 2036, at a CAGR of 7.0%. This growth is driven by increasing adoption of advanced neuromodulation, expansion of closed-loop and personalized neuromodulation, and strategic portfolio consolidation among key players. Implantable devices, cardiovascular applications, and hospitals are expected to maintain their leading positions in the market segments.
Medtronic to Buy Contego Medical for $380M to Bolster Stroke-Prevention Portfolio
Medtronic is set to acquire privately held Contego Medical for $380 million, plus potential post-closing payments, to enhance its portfolio in carotid artery disease and peripheral thrombectomy. This deal follows an exclusive U.S. distribution agreement and centers on Contego's FDA-approved Neuroguard IEP Direct System, which demonstrated excellent clinical outcomes in stroke prevention. The acquisition is expected to minimally dilute Medtronic's adjusted EPS in fiscal 2027-2028 before becoming neutral to accretive.
Medtronic’s Hugo robot gets expanded FDA clearance in general surgery
Medtronic's Hugo robotic surgery system has received expanded FDA clearance for use in general surgery procedures, including upper and lower abdominal surgeries. This clearance significantly broadens Hugo's market reach, covering over half of the soft tissue procedures performed annually in the U.S. Medtronic aims to leverage its existing expertise in general surgery to further penetrate the robotic surgery market, where it is experiencing rapid global growth with its Hugo system.
InspireMD to Host KOL Webinar on Carotid Artery Disease Management and the Clinical Benefits of InspireMD’s CGuard Prime Carotid Stent Platform
InspireMD, Inc. (Nasdaq: NSPR) announced it will host a Key Opinion Leader (KOL) webinar on November 19, 2026, to discuss carotid artery disease management and the benefits of its CGuard Prime carotid stent platform. The webinar will feature six physician experts and highlight the CGuard Prime system's unique MicroNet™ mesh technology, recently approved by the FDA for TCAR procedures. This platform is estimated to address approximately 75,000 carotid stenting procedures annually in the U.S.
Orchestra BioMed to Participate in Piper Sandler 38th Annual Healthcare Conference
Orchestra BioMed Holdings, Inc. (OBIO) announced its participation in the Piper Sandler 38th Annual Healthcare Conference, where CEO David Hochman will engage in a fireside chat on December 2, 2026. The company is advancing two product candidates, AVIM Therapy and Virtue® Sirolimus AngioInfusion™ Balloon, both with FDA Breakthrough Device Designations and currently in pivotal clinical trials. These innovations address multi-billion-dollar market opportunities in hypertension and atherosclerotic artery disease, respectively, with a live webcast of the event available on the company's Investor Relations site.
This Medtronic Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
Top Wall Street analysts have updated their ratings for several companies, with Medtronic plc among them. Piper Sandler analyst Matt O’Brien upgraded Medtronic from Neutral to Overweight, raising its price target. Other companies receiving upgrades include United Natural Foods, Zimmer Biomet Holdings, Nucor Corporation, and Praxis Precision Medicines.
Medtronic gets FDA clearance for Hugo general surgery
Medtronic (NYSE: MDT) has received FDA clearance for its Hugo robotic surgery system to be used in general surgery, expanding its application beyond urology. This expanded indication covers approximately 3.5 million procedures annually in the U.S., including various upper and lower-abdominal surgeries. The company expects worldwide Hugo procedures to exceed 50,000 by its fiscal year-end, signaling significant growth potential in the competitive robotic surgery market.
Medtronic upgraded by Piper Sandler with a new price target
Piper Sandler has upgraded Medtronic (MDT) from Neutral to Overweight, setting a new price target of $120.00. This upgrade comes as Medtronic stock was trading at $102.90 at the time of the news. Historical data suggests that after analyst upgrades, Medtronic's stock has closed higher three out of five times in the next trading session over the past year.
ISRG EPS Climbs 25% to $3: Is Innovation Driving Profitable Growth?
Intuitive Surgical (ISRG) reported strong adjusted earnings growth in Q3 2026, with EPS up 25% to $3 and revenue increasing 22% to over $3 billion, driven by the adoption of its robotic platforms and improved operating efficiency. The company continues to invest heavily in innovation, including AI capabilities for its da Vinci 5 system and new instrumentation, which is reflected in increased R&D expenses. While adjusted profit rose significantly, GAAP net income declined due to a $450 million litigation settlement.
Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system
Medtronic plc has announced that its Hugo™ robotic-assisted surgery (RAS) system has received FDA clearance for use in general surgery procedures. This expanded clearance includes upper and lower abdominal procedures, covering a significant portion of all soft-tissue surgeries performed annually in the U.S. The move aims to provide hospitals with more flexibility in addressing capacity challenges and offering advanced surgical options to patients.
Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system
Medtronic plc announced that its Hugo™ robotic-assisted surgery (RAS) system has received U.S. FDA clearance for use in general surgery procedures, expanding its application beyond urology. This clearance covers a wide range of upper and lower abdominal procedures, which account for over half of all soft-tissue surgeries annually in the U.S. The Hugo RAS system's modular design and integration with Medtronic technologies like the LigaSure™ RAS Maryland instrument aim to provide greater flexibility and accessibility for surgical teams and patients.
Orchestra BioMed to Participate in the Piper Sandler 38th Annual Healthcare Conference
Orchestra BioMed Holdings, Inc. announced its participation in the Piper Sandler 38th Annual Healthcare Conference from December 1-3, 2026, in New York City. CEO David Hochman will participate in a fireside chat and management will hold one-on-one investor meetings. The company is advancing two flagship product candidates, AVIM Therapy for hypertension and Virtue® Sirolimus AngioInfusion™ Balloon for atherosclerotic artery disease, both currently in pivotal clinical trials.
Medtronic's First Clean Quarter Since Its Extra Week Tests Whether Acceleration Is Real
Medtronic's upcoming fiscal second-quarter report will be crucial in determining if the strong organic growth seen in the previous quarter, which was boosted by an extra selling week, is sustainable. Wall Street analysts and management have differing expectations for full-year earnings and revenue, with the second quarter providing a key test of the company's acceleration in areas like cardiac rhythm, cranial and spinal, and surgical segments. The market has already reacted positively to the prior report, but sentiment has cooled, indicating caution regarding the impact of the extra week's absence.
AECOM shares rise after earnings, but construction cash costs linger
AECOM's shares rose after its latest earnings report, which showed stronger adjusted profit and a dividend increase. While the company exceeded its earlier free cash flow forecast, concerns remain about turning earnings into actual cash due to lingering costs from two Construction Management projects. The company's future performance hinges on successful execution and managing these project commitments.
Acadia Pharma to commercialise DAYBUE® STIX (trofinetide) in Japan for treatment of Rett syndrome
Acadia Pharmaceuticals has signed an exclusive distribution agreement with KYORIN Pharmaceutical to commercialise DAYBUE® STIX (trofinetide) in Japan for treating Rett syndrome. Acadia will receive an upfront payment of $30 million, potential future regulatory and sales milestones, and a share of net sales. This follows Acadia's completed Phase 3 study in Japan, which showed results consistent with its pivotal LAVENDER™ Phase 3 study.
Senseonics and Beta Bionics Launch Eversense® 365 and iLet® Bionic Pancreas Integration
Senseonics and Beta Bionics have commercially launched the integration of Eversense 365, a year-long implantable continuous glucose monitor, with the iLet Bionic Pancreas for automated insulin delivery. This system autonomously determines insulin doses without requiring carbohydrate counting, aiming to simplify diabetes management. The companies also plan future integration with Beta Bionics' Mint tubeless patch pump to broaden insulin delivery options.
MiniMed's Second Standalone Quarter Must Show Flex Demand Can Outrun Fading Margin Patience
MiniMed, an independent company, is facing scrutiny as its stock has fallen despite strong first-quarter performance. The upcoming fiscal second-quarter earnings release on November 24 will be a critical test, with analysts expecting $0.10 earnings per share on $827.5 million revenue. The market is looking for validation of demand growth, particularly for its Flex pump, and clearer signs of progress towards its 16% full-year EBITDA margin target, as current profitability remains a concern.
MiniMed and Tandem win FDA clearance for their first tubeless insulin pumps, setting up a 2027 fight with Insulet
MiniMed Group and Tandem Diabetes Care have both received FDA clearance for their first tubeless insulin pumps, setting the stage for a competitive market in 2027 against current leader Insulet. MiniMed Fit, with a seven-day wear time and 300-unit capacity, will launch in spring 2027, while Tandem's tubeless Mobi kit, offering a seven-day infusion set and 200-unit cartridge, is planned for the first half of 2027. Both companies aim to challenge Insulet's Omnipod, which currently dominates the tubeless pump market with a three-day wear time.
Medtronic agrees to buy carotid stent maker Contego Medical for $380 million
Medtronic announced its agreement to acquire Contego Medical, a private developer of carotid artery disease and peripheral thrombectomy devices, for $380 million, with potential additional payments. This acquisition expands Medtronic's portfolio with Contego's FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices, aiming to strengthen its leadership in carotid revascularization. The deal is expected to close in Medtronic's fiscal third quarter and will have minimal impact on adjusted EPS in the near term, becoming neutral to accretive thereafter.
Is Abbott Laboratories (ABT) Undervalued On Medical Devices Growth And New Rapid Tests?
Abbott Laboratories (ABT) is gaining attention due to momentum in its Medical Devices unit, particularly with electrophysiology products and new rapid testing offerings. Despite a 12.62% year-to-date share price decline, analysts consider ABT undervalued with a fair value of $120.26, contingent on continued growth in medical technology and managing Nutrition legal risks. However, its P/E ratio of 40.2x is higher than industry averages, suggesting limited upside if market sentiment shifts.
MiniMed gets FDA nod for tubeless insulin pump
MiniMed has received FDA clearance for its first tubeless insulin pump, the MiniMed Fit, designed for individuals with Type 1 and Type 2 diabetes aged seven and older. The device can be worn for up to seven days, holds 300 units of insulin, and features a meal detection algorithm. MiniMed aims to compete with Insulet and Tandem Diabetes Care in the patch pump market, with a phased U.S. rollout planned for spring 2027.
Medtronic Targets Stroke Prevention Technologies in $380 Million Contego Deal
Medtronic announced its intention to acquire Contego Medical for $380 million, expanding its offerings in carotid artery disease and peripheral thrombectomy. This acquisition includes Contego’s FDA-approved Neuroguard IEP Direct System for transcarotid artery revascularization and Excipio thrombectomy devices. Medtronic expects the deal to minimally dilute adjusted earnings per share in fiscal years 2027 and 2028 before becoming accretive.
Medtronic Targets Stroke Prevention Technologies in $380 Million Contego Deal
Medtronic Plc announced its intent to acquire Contego Medical in a $380 million deal to expand its offerings for carotid artery disease and peripheral thrombectomy. This acquisition includes Contego’s FDA-approved Neuroguard IEP Direct System, which combines flow reversal with integrated embolic protection for transcarotid artery revascularization, and their Excipio thrombectomy devices. Medtronic expects the deal to minimally dilute adjusted earnings per share in fiscal years 2027 and 2028 before becoming neutral to accretive thereafter.
Medtronic to buy Contego Medical for $380M
Medtronic announced its plan to acquire Contego Medical, a privately held medical device company specializing in carotid artery disease and peripheral thrombectomy technologies, for $380 million with potential post-acquisition payments. This acquisition aims to bolster Medtronic's portfolio in carotid disease treatments, building on a previous distribution agreement with Contego, and is expected to be minimally dilutive to Medtronic’s adjusted earnings per share in fiscal 2027 and 2028 before becoming neutral to accretive. Contego's Neuroguard IEP carotid stent system and Excipio thrombectomy device will complement Medtronic's existing offerings, positioning Medtronic as a leader in carotid revascularization.
Medtronic plans US$380M Contego Medical acquisition for vascular portfolio
Medtronic plc announced plans to acquire privately held Contego Medical, Inc. for US$380 million, expanding its carotid-artery and clot-removal portfolio. The deal, which includes potential later payments and is expected to close in Medtronic's fiscal third quarter, is projected to cause a small reduction in Medtronic's adjusted earnings per share in fiscal 2027 and 2028 before becoming neutral or positive after fiscal 2028. This acquisition builds on an existing distribution agreement and integrates Contego's Neuroguard IEP Direct System and Excipio thrombectomy devices into Medtronic's offerings.
Medtronic to acquire Contego Medical in $380 million deal
Medtronic announced its intent to acquire Contego Medical, a privately held medical device company, for $380 million, with potential post-acquisition payments. This acquisition builds on an existing exclusive US distribution agreement and includes the FDA-approved Neuroguard IEP Direct System and Excipio thrombectomy devices. The deal is expected to be minimally dilutive to Medtronic's adjusted EPS in FY27 and FY28, becoming neutral to accretive thereafter.
Medtronic to acquire Contego Medical, expanding access to next-generation carotid therapies
Medtronic announced its intent to acquire Contego Medical, a privately held medical device company specializing in solutions for carotid artery disease and peripheral thrombectomy. This acquisition builds on an existing distribution agreement and aims to strengthen Medtronic's leadership in carotid artery disease treatment by incorporating Contego's innovative technologies, including the recently FDA-approved Neuroguard IEP™ Direct System. The deal, valued at $380 million with potential post-acquisition payments, is expected to close in Medtronic's fiscal third quarter and be minimally dilutive to adjusted EPS in FY27 and FY28.
Medtronic to acquire Contego Medical for $380 million
Medtronic plc announced its intent to acquire Contego Medical for $380 million, with potential for additional payments. This acquisition will expand Medtronic's portfolio in carotid artery disease and peripheral thrombectomy solutions, building on a previous distribution agreement. Medtronic expects the deal to be minimally dilutive to earnings per share in fiscal years 2027 and 2028, becoming neutral to accretive thereafter.
5 Dividend Stocks to Buy and Hold Forever
This article recommends five reliable dividend stocks—Johnson & Johnson (JNJ), Medtronic (MDT), Procter & Gamble (PG), Federal Realty (FRT), and Realty Income (O)—as long-term investments. These companies are highlighted for their consistent dividend increases, strong business models, and potential to provide a steady income stream for investors looking for "buy and hold forever" options. The article details why each company is a good investment, focusing on their industry resilience and financial performance.
Endobronchial Tubes Market Size, Share & Forecast 2036
The Endobronchial Tubes Market is projected to grow from USD 416.2 million in 2026 to USD 739.1 million by 2036, at a CAGR of 5.9%. This growth is driven by the increasing demand for advanced airway management in complex thoracic procedures and the adoption of visualization-enabled lung isolation devices. Double-lumen tubes are expected to maintain their lead in product demand, particularly with integrated video capabilities.
Earnings Beat Could Be A Big Moment For Abbott Stock And Nutrition Split Plans
Abbott Laboratories recently reported strong third-quarter 2026 sales and earnings across key segments and announced plans to spin off its global Nutrition business into a separate public company by late 2027. The company's focus is now on how this spin-off and its medical devices pipeline will reshape its investment narrative, alongside ongoing efforts in diagnostics and margin expansion. Analysts are watching for execution on margins and the concentration of risk related to the Nutrition segment, while new product launches like the Panbio COVID-19/Flu A&B Self Test contribute to the diagnostics growth story.